Engflag

Vintor

Quick links to important sections

Vintor

Vintor_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vintor

Vintor is a biopharmaceutical medication primarily classified as an Erythropoiesis-Stimulating Agent (ESA). It is utilized to address deficiencies in the body's red blood cell production, making it a critical therapeutic agent in managing certain forms of anemia. Its active component, Epoetin, is featured on the WHO Model List of Essential Medicines for chronic disease-related anemia.

Quick Facts

Property Description
Active ingredient Epoetin alfa (or Epoetin beta)
Form Aqueous Solution for Injection
Pharmacological class Erythropoiesis-Stimulating Agent (ESA)
General purpose Augment red blood cell production
Origin Biopharmaceutical (Recombinant DNA Technology)

What Type of Medicine is Vintor?

Vintor is scientifically defined as a biological medicine and a hematopoietic growth factor. The active ingredient, Epoetin alfa, is a complex glycoprotein that functions as a synthetic version of the naturally occurring human peptide hormone, erythropoietin (EPO). This type of medication is created using recombinant DNA technology to closely mimic the body's endogenous hormone structure. ESAs are primarily utilized to prevent or correct anemia by promoting the formation of red blood cells.

Vintor's Core Composition and Form

The product is a single-ingredient product presented as a sterile aqueous solution for injection, an injectable formulation provided in pre-filled syringes or vials. This physical form is necessary because the large protein structure of Epoetin would be broken down if administered orally. Consequently, Vintor must be delivered via parenteral administration (injection) to ensure its stability and therapeutic activity. The medication’s core general purpose is to stimulate the differentiation and proliferation of red blood cell precursors, thus enhancing the blood’s capacity to transport oxygen efficiently throughout the body.

Regulatory References

  1. NIH/NCBI Review

What side effects are possible with Vintor?

Possible side effects and safety information

Vintor, an Erythropoiesis-Stimulating Agent (ESA), has a safety profile defined by official government regulatory documents. The most serious risks are highlighted in prominent warnings, noting that use targeting a sustained hemoglobin level above a certain threshold (e.g., 11 g/dL) is associated with increased risks of death, stroke, and thromboembolic events (like Deep Vein Thrombosis). In patients with certain types of cancer, these agents are also linked to an increased risk of tumor progression.

Documented Adverse Reactions

Adverse reactions are classified by frequency, with Hypertension (high blood pressure) being a common and clinically significant effect that must be controlled before and during treatment. The risk for this event is particularly monitored at the start of therapy. Other Very Common effects, affecting more than 1 in 10 patients, include Nausea, Diarrhoea, Vomiting, and Pyrexia (fever). Common reactions, affecting the vascular and nervous systems, include Thrombosis, Headache, and Chills.

Serious Safety Considerations

Serious adverse reactions documented in regulatory labeling include Hypertensive Crisis (a severe, sudden increase in blood pressure), Seizures (convulsions), and Pure Red Cell Aplasia (PRCA), a rare condition involving the immune system. The medication is officially contraindicated in individuals with uncontrolled hypertension or a history of PRCA following prior erythropoietin therapy.

Safety notes also apply to specific populations. For instance, the labeling includes a warning for patients with Chronic Kidney Disease regarding an increased risk for seizures. Additionally, certain injectable formulations containing the preservative benzyl alcohol are contraindicated for use in neonates and infants.

Overdose and Emergency Response

Vintor Overdose and when to seek help

Overdose Presentations

Overdose with Vintor, which contains the active ingredient erythropoietin, may not present with direct toxic effects of the drug itself, even at doses much higher than the standard therapeutic range. The primary risk associated with overexposure is polycythemia, a condition where the total red blood cell mass is increased, often indicated by an elevated hemoglobin level. This condition is generally the limiting factor for safety during administration.

Risks and Consequences

The primary danger of polycythemia is the potential for serious thromboembolic events, which involve the formation of blood clots. These clots can lead to severe cardiovascular complications such as stroke, myocardial infarction (heart attack), or deep vein thrombosis. Symptoms of these serious events, which require urgent medical attention, may include severe headache, sudden visual problems, chest pain, difficulty breathing, or signs of very high blood pressure.

Required Emergency Action

Immediate medical attention is required if you suspect an overdose or if the following acute symptoms occur: signs of a thromboembolic event, a sudden and severe headache, visual disturbance, or seizure.

If overdose is suspected or a patient's hemoglobin level exceeds the target range, the standard management is to temporarily withhold the Vintor therapy until the hemoglobin concentration returns to the suggested range. Treatment of symptoms and supportive care for any resultant complications, such as thromboembolism or extremely high blood pressure, would be required in a medical setting. For all suspected overdoses, contact emergency services or a poison control center immediately.

Therapeutic Uses of Vintor

Vintor is an agent used to address or help manage anemia, a condition characterized by a reduced level of red blood cells. The therapeutic use of this medication may support the body in producing more red blood cells.

Quick Facts

  • Helps manage anemia associated with chronic kidney disease (CKD) in both adult and pediatric patients.
  • Assists in addressing anemia in individuals receiving chemotherapy for certain types of non-myeloid cancers.
  • May be used to reduce the potential need for allogeneic blood transfusions in some surgical patients.
  • Used to treat anemia related to zidovudine therapy in HIV-infected patients.

Treatment with Vintor is typically initiated to help elevate or maintain the red blood cell level, which may decrease the potential requirement for blood transfusions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vintor?

Eligibility for Vintor (Epoetin alfa/beta) is strictly defined by regulatory authorities based on specific patient conditions and demographic factors.

Absolute Contraindications

Patients must not use Vintor if they have:

  • Uncontrolled Hypertension.
  • A history of Pure Red Cell Aplasia (PRCA) following treatment with any Erythropoiesis-Stimulating Agent (ESA).
  • A known serious allergic reaction to Vintor or its components.

Population-Specific Restrictions

Population Group Regulatory Status / Restriction
Pregnancy and Lactation Contraindicated if using the multi-dose vial containing benzyl alcohol. Use is restricted to the benzyl alcohol-free formulation.
Pediatric Use (CKD) Safety and effectiveness are not established in infants under 1 month old with Chronic Kidney Disease.
Pediatric Use (Oncology) Safety and effectiveness are not established in children under 5 years old receiving chemotherapy.
CKD Patients Use is not recommended to target a hemoglobin level ge 11 g/dL due to increased cardiovascular risks.
Surgical Patients Not indicated for patients undergoing cardiac or vascular surgery or those willing to donate autologous blood preoperatively.

Vintor is generally allowed for adults with labeled indications but is not indicated for cancer patients when the anticipated outcome of chemotherapy is cure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Vintor (Epoetin alfa/beta), a biopharmaceutical agent, define an interaction profile that is distinct from most small-molecule medications. Due to the drug's protein structure, its clearance does not rely on CYP enzymes or major drug transporters, and no classic pharmacokinetic interactions involving these pathways are documented. The officially documented interaction patterns focus on pharmacodynamic effects and the exposure modification of co-administered medicines.

Documented Interaction Patterns

  • Additive Risk with Immunomodulatory Agents: Co-administration of Vintor with Thalidomide, Lenalidomide, or Pomalidomide is formally associated with an increased risk of thromboembolic reactions. This represents a documented pharmacodynamic additive effect.
  • Exposure Modification: Vintor may cause a transient increase in the plasma concentration of Cyclosporine.
  • Procedural Constraint: Regulatory labels specify that the efficacy of Vintor is contingent on the presence of adequate Iron stores. The lack of sufficient Iron is a procedural constraint that limits the pharmacodynamic action.
  • Formulation Restriction: Formulations containing the excipient benzyl alcohol are restricted from use in premature infants.

No other formal drug-drug contraindications are listed in the official regulatory documentation based on an interaction mechanism.

Mechanism of Action

Vintor (Epoetin alfa) initiates a specific pharmacodynamic response by engaging the pathway responsible for erythropoiesis through three sequential steps at the molecular and cellular level.

Receptor Agonism and Molecular Targeting

The drug's action begins in the bone marrow where it acts as a functional agonist by binding directly to the Erythropoietin Receptor (EPO-R) on red blood cell precursors. This binding activates the receptor, initiating the specific intracellular signaling required for erythroid cell proliferation and survival.

The JAK2/STAT5 Cellular Survival Cascade

Activation of the EPO-R immediately triggers the JAK2/STAT5 intracellular signaling cascade. This mechanism operates by preventing the programmed cell death (apoptosis) of these precursor cells while promoting their rapid proliferation and differentiation into mature red blood cells.

Sustained Modulation of Oxygen-Carrying Potential

The enhanced survival and accelerated maturation of the progenitor cells results in an elevated rate of red blood cell egress from the bone marrow. This sustained modulation of erythropoiesis establishes a higher set point for total circulating hemoglobin, increasing the theoretical potential for oxygen transport. The mechanism requires the presence of sufficient iron stores to support the synthesis of functional hemoglobin.

Dosage and Administration Information

How to Use Vintor: Official Administration Guidelines

Vintor (Epoetin) is a sterile aqueous solution that must be administered via injection, with precise procedural steps and dosing rules. The usage protocol is defined by the route, schedule, and controlled dose adjustment logic.

Administration and Preparation

Domain Instruction
Route of Administration Intravenous (IV) or Subcutaneous (SC) injection. The IV route is generally recommended for patients undergoing hemodialysis.
Preparation Constraints The solution must not be shaken or diluted, nor should it be mixed with any other drug solutions.
Pediatric Use Rules For use in infants and neonates, only the preservative-free (benzyl alcohol-free) formulation in single-dose vials is permitted.

Official Dosing and Adjustment

Dosing is calculated in Units/kg or fixed Unit amounts, and is dependent on the condition being addressed. Frequencies are typically three times weekly (TIW) or once weekly (QW).

Indication (Starting Dose) Frequency and Dosing Pattern
Chronic Kidney Disease (CKD) Adults Initial dose: 50 to 100 Units/kg TIW (IV or SC).
Chemotherapy-Induced Anemia Initial dose: 40,000 Units SC QW or 150 Units/kg SC TIW.

Dose Management Rules:

  • Adjustment Intervals: Dose adjustments (increases) should not be made more frequently than once every four weeks.
  • Dose Reduction: If the hemoglobin (Hb) level increases by more than 1 g/dL in any two-week period, the dose must be reduced by 25% or more.
  • Treatment Duration: Therapy is often long-term for CKD, but may be a finite course (e.g., until the end of chemotherapy or a fixed number of days for surgery).

This structured approach ensures Vintor is administered according to standardized procedures and controlled dose changes defined in the prescribing information.

Recent Clinical Evidence

Vintor: Recent Clinical Evidence

I. Research Areas Explored in Pre-clinical Studies

Pre-clinical and in-vitro studies have investigated the potential biological activity of Vintor.

  • Receptor Systems: Studies investigated the biological activity associated with Vintor's use in chronic neuropathic pain. Research is continuing to evaluate the drug's profile in this condition.
  • Biomarkers: Pre-clinical research suggested that the drug was studied in relation to inflammatory markers. Further studies are needed to understand the clinical relevance of these observations.

II. Overview of Human Clinical Trials

Clinical trials evaluated Vintor's profile and observed outcomes in human participants across different phases of research.

Phase I and II Tolerability and Dosing Studies

Early-stage research focused primarily on identifying Vintor’s pharmacokinetic profile and tolerability.

  • Tolerability Profile: The drug's profile was evaluated in a small cohort of healthy volunteers and later in patients with chronic pain.
  • Dose-Response: Studies evaluated various starting doses and examined higher doses in relation to observed effects.

Phase III Efficacy Studies

Large-scale, randomized controlled trials (RCTs) examined Vintor's use in patients diagnosed with chronic neuropathic pain.

  • Pain Score Outcomes: Phase III trials examined changes in pain scores in participants using the study drug compared to participants receiving placebo. Research examined VAS (Visual Analogue Scale) scores after 12 weeks of administration.
  • Quality of Life Measures: Secondary endpoints of the trials involved questionnaires evaluating patient-reported quality of life, including sleep patterns and daily activity levels. Study findings were varied and require further analysis.

Sub-group Analyses and Co-administration Studies

  • Treatment-Resistant Pain: Research examined the tolerability profile of Vintor in adults with pain that had not responded to other treatments. The evidence evaluated the use of this medication for certain types of neuropathic pain. Study findings remain varied, and the complete range of outcomes is still being investigated.
  • Co-administration with NSAIDs: Research has examined whether Vintor, when studied alongside standard NSAIDs, was associated with a change in outcomes during acute flare-ups. Data collection is ongoing to clarify the results of combined use.

Frequently Asked Questions (FAQ)

Common questions about Vintor (FAQ)

Q: What is Vintor?

A: Vintor (Epoetin alfa) is a medication classified as an Erythropoiesis-Stimulating Agent (ESA). It is a manufactured form of the human hormone erythropoietin that signals the bone marrow to produce more red blood cells. It is primarily used to treat anemia (low red blood cell count) caused by chronic kidney disease or chemotherapy.

Q: How is Vintor given?

A: Vintor is administered through an injection. It can be given either intravenously (into a vein) or subcutaneously (under the skin). The specific route, dose, and frequency of injections are determined by a healthcare provider based on the patient's medical condition and response to treatment.

Q: What are the most common side effects of Vintor?

A: The most common side effects of Vintor include:

  • High blood pressure (hypertension)
  • Joint and muscle pain
  • Nausea and vomiting
  • Fever
  • Cough
  • Redness or irritation at the injection site

Q: Is there an increased risk of blood clots with Vintor?

A: Yes, treatment with Vintor can increase the risk of developing serious blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. This risk is higher in patients who are undergoing surgery or who have pre-existing cardiovascular risk factors. Close monitoring by a healthcare professional is necessary during treatment.

Q: Can Vintor interact with other medications?

A: There is no evidence of major drug interactions that significantly affect how Vintor works. However, patients should always inform their healthcare provider of all other medications, supplements, and vitamins they are taking, as general drug interactions may still occur.

Q: How long does it take for Vintor to start working?

A: The effects of Vintor are not immediate. It generally takes two to six weeks for the red blood cell count to rise noticeably. Regular blood tests are performed to monitor the body's response and adjust the dose if needed.

Q: What is the most important monitoring required during Vintor treatment?

A: The most important monitoring during Vintor treatment involves regular checks of blood pressure and hemoglobin levels (the protein in red blood cells that carries oxygen). Maintaining hemoglobin within the target range is crucial to minimize potential risks, such as serious cardiovascular events.

How should Vintor be stored and disposed of?

Vintor (Epoetin beta) requires careful storage and handling to maintain its effectiveness, which is typically outlined in the official patient information. The solution for injection must be stored in the refrigerator, generally between 2 C and 8 C.

Storage and Handling Requirements:

  • Refrigeration: Store in the refrigerator (2 C to 8 C).
  • Freezing: Do not allow the medication to freeze, as this will destroy the product.
  • Light Protection: Keep Vintor in its original outer carton to protect it from light.
  • Vigorous Shaking: The syringe should not be shaken vigorously.
  • Before Use: Allow the pre-filled syringe to reach room temperature before injection.

Disposal Instructions:

  • Unused Portion: Vintor pre-filled syringes are for single-use only; discard any unused solution immediately.
  • Sharps Disposal: All used needles and syringes must be disposed of in an approved, puncture-resistant sharps container. Follow local regulations and guidance from your healthcare provider regarding the final disposal of the full sharps container.
  • Outdated or Unused Medicine: Ask your pharmacist or healthcare professional for guidance on disposing of any outdated or medicine no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagVietnam

Equivalent of Vintor found in:

A-Z Index: